Evidence map›Paper›PMID 41051912›Full record

ArticleEpilepsia open2025

Late-onset epilepsy of unknown etiology is more treatment-responsive than acquired lesional late-onset epilepsy.

L Brian Hickman, Bhavya Pandey, Alexander Fish, Mohit Bandla, Adnan Husein, Corinne Allas, Harika Kottakota, Lauren Herzog, Keith Vossel, John M Stern

Abstract read
In one paragraph

Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

L Brian HickmanDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-7685-9562
Bhavya PandeyDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Alexander FishDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Mohit BandlaDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Adnan HuseinDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Corinne AllasDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Harika KottakotaDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Lauren HerzogDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Keith VosselDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
John M SternDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Funding

IN VIVO STUDIES OF THE EPILEPTIC HIPPOCAMPUSR01NS033310 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JEROME NONE ENGEL, Richard Staba · 1994 to 2026
$7.5M
Astrocyte and neuron brain-region and compartment-specific proteome dynamics in aging and Alzheimer’s diseaseR01AG075955 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KHAKH, BALJIT, VOSSEL, KEITH ALAN · 2021 to 2025
$5.2M
Leveraging the Electronic Health Record and Integrating Social and Biological Data to Expand Dementia Research in Understudied Populations in Los Angeles CountyUH3AG083254 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Keith Alan Vossel · 2025 to 2026
$2.3M
Preventing Seizures and Associated Memory Loss in Alzheimer's Disease by Blocking Tau Interactions with SH3-containing Proteins.R01AG058820 · NIA · UNIVERSITY OF MINNESOTA · PI VOSSEL, KEITH ALAN · 2019 to 2023
$1.9M
UCLA Neuroscience Physician-Scientist Training ProgramUE5NS065723 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Stanley Thomas Carmichael, Jason D Hinman · 2024 to 2026
$1.2M
Leveraging the Electronic Health Record and Integrating Social and Biological Data to Expand Dementia Research in Understudied Populations in Los Angeles CountyUH2AG083254 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOSSEL, KEITH ALAN · 2023 to 2024
$1.1M
Alpha-Synuclein Induced Network Hyperexcitability in Lewy Body DementiasR56AG074473 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LEE, MICHAEL K, MOORE, DARREN JOHN · 2021 to 2021
$840k
NIA NIH HHS R01 AG058820NIA NIH HHS R01 AG075955NIA NIH HHS R56 AG074473NIA NIH HHS UH2 AG083254NIA NIH HHS UH3 AG083254NINDS NIH HHS R01 AG058820NINDS NIH HHS R01 AG075955NINDS NIH HHS R01 NS033310NINDS NIH HHS R56 AG074473NINDS NIH HHS UE5 NS065723NINDS NIH HHS UE5 NS065723-16NINDS NIH HHS UH2 AG083254
6 · The paper itself

Abstract

objectiveLate-onset epilepsy of unknown etiology (LOEU) carries an elevated risk of dementia, suggesting that it may represent an early manifestation of neurodegenerative or cerebrovascular disease. Direct comparisons between LOEU and acquired lesional late-onset epilepsy (LOE) may elucidate clinical features specific to LOEU.

methodsWe performed a retrospective chart review of patients with LOE, with first documented seizure at age 55 or older, whose evaluation included an epilepsy-protocol brain MRI and/or inpatient video-EEG evaluation. Etiology was determined from neuroimaging lesions and medical history. Patients without an identified etiology were categorized as LOEU. Analyses were performed controlling for sex, age of onset, and epilepsy duration.

resultsWe identified 75 LOEU (mean onset: 64.9 years, 38.7% female) and 57 acquired lesional LOE cases with etiologies including cortical stroke, hemorrhage, neoplasm, trauma, or infection (mean onset: 66.5 years, 36.8% female). LOEU was less likely to have a history of status epilepticus (6.7% vs. 21.1%, aOR: 0.28, p < 0.03) or to have undergone inpatient video-EEG monitoring (13.3% vs. 24.6%, aOR: 0.34, p < 0.04). LOEU was prescribed fewer ASMs compared to acquired lesional LOE (aOR: 0.43, p < 0.02), and LOEU patients prescribed multiple ASMs had lower average 12-month seizure frequency than acquired lesional LOE (median: 0.2 vs. 1.0, p < 0.01). LOEU had lower rates of vascular comorbidities than acquired lesional LOE, though rates of subsequent dementia were not significantly different (5-year risk: 16.6% vs. 17.7%). An exploratory cluster analysis demonstrated an LOEU subgroup with older onset, higher prevalence of white matter hyperintensities, cerebral atrophy, epileptiform discharges, and greater epilepsy severity. SIGNIFICANCE: LOEU was associated with fewer proxies for epilepsy severity, signifying that LOEU is more often treatment-responsive than acquired lesional LOE. LOEU has lower rates of comorbid vascular disease compared to acquired lesional LOE, suggesting that occult cerebrovascular disease is not overrepresented in LOEU relative to other forms of LOE. PLAIN LANGUAGE SUMMARY: People who develop epilepsy after age 55 without a known cause usually respond well to treatment and need fewer antiseizure medications than people with epilepsy from a known brain injury. In this study, they had fewer hospital stays for seizure monitoring and fewer vascular problems. Dementia risk was high in patients with late-onset epilepsy, both when the cause was known and when it was unknown. Late-onset epilepsy without a known cause is often less severe but still needs regular monitoring for memory and thinking problems.

Indexed as

AnticonvulsantsEpilepsyAgedAged, 80 and overAge of OnsetElectroencephalographyFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesAnticonvulsantsAlzheimer's diseasecerebrovascular diseaseelderlyepilepsylate‐onset epilepsyneurodegenerative disease

Identifiers

PMID41051912
PMCPMC12716292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.